{"id":"budesonide-cfc","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is an inhaled corticosteroid that reduces airway inflammation by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators and recruitment of immune cells. The CFC formulation refers to the chlorofluorocarbon propellant used in the metered-dose inhaler delivery system. It is used to prevent and control asthma symptoms and reduce airway hyperresponsiveness.","oneSentence":"Budesonide is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:05.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (maintenance and prevention)"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT00667992","phase":"PHASE3","title":"Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Asthma","enrollment":99},{"nctId":"NCT00660569","phase":"","title":"Utilization Patterns of Pulmicort in Real Life Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Asthma","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Budesonide CFC","genericName":"Budesonide CFC","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs. Used for Asthma (maintenance and prevention), Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}